Summary DBA/2NCrIBR Fl mice received a single i.v. injection of doxorubicin (4.32, 7.20 or 12.00mgkg-'), cyclophosphamide (70, 120 or 200mgkg-1) or cis-diamminechloroplatinum (5.4, 9.0 or 15.0mgkg-'), alone or 2h before an i.p. injection of 1,000mgkg-' of diethyldithiocarbamate (DDTC). Twenty-four hours after, survival of bone marrow colony forming units-spleen and granulocyte-macrophage colony forming cells, was determined. On the whole, administration of DDTC reduced the toxic effect of the three anticancer drugs on haemopoietic progenitors. The effect was in general more evident at the lower than at the higher doses of the antitumour drugs.
Among drugs that protect against toxicity of antineoplastic agents, thiocompounds are receiving ever increasing attention. As a result of their intrinsic selectivity of action or following administration at an appropriate time with respect to the antitumour drug or in separate body compartments (Howell et al., 1983) , the protective effects of selected thiols on normal tissues seem to be unaccompanied by concomitant protection on tumour cells Borch et al., 1980; Brock & Pohl, 1983; Meinstrich et al., 1984; Bodenner et al., 1986a, b) . In experimental studies, renal, gastrointestinal and general toxicity of cis-diamminedichloroplatinum (cis-DDP), cardiotoxicity of doxorubicin (DX) and general and bladder toxicity of cyclophosphamide (CY) were reduced by administration of diethyldithiocarbamate (DDTC), sodium thiosulphate, n-acetyl-cysteine, mesna and WR2721 Brock & Pohl, 1980; Meinstrich et al., 1984; Borch & Pleasants, 1979; Bodenner et al., 1986a, b; Howell & Taettle, 1983; Doroshow et al., 1981; Glover et al., 1984; Allan et al., 1986) .
Studies on the effects of thiocompounds on bone marrow toxicity, which is a major dose-limiting effect of most anticancer drugs, have given contrasting results. In vivo DDTC and WR2721 afford protection against cis-DDP and CY toxicity on mice bone marrow haemopoietic progenitors and peripheral blood leukocytes in mice (Brock & Pohl, 1983; Wasserman et al., 1981; Gringeri & Borch, 1984) . In vitro, sodium thiosulphate reduces the toxicity of cis-DDP on mice bone marrow granulocytemacrophage colony forming cells (GM-CFC) (Howell & Taetle, 1980) . In contrast, mesna had no protective effect on mice bone marrow colony forming units spleen (CFU-S) against CY toxicity (Millar et al., 1983) , and in our previous experiences no effect of n-acetylcysteine, on pluripotent and committed haemopoietic stem cells of mice treated with CY, DX or cis-DDP was found (Massa et al., 1985; Lerza et al., 1986) .
The present study was carried out to determine whether DDTC could reduce DX, CY or cis-DDP toxicity on murine pluripotent (CFU-S) and committed (GM-CFC) haemopoietic stem cells. The anticancer drugs were selected for their clinical relevance and because, according to the above-cited studies, one or more of their toxic effects were reduced by administration of thiocompounds. DDTC is related to disulphiram, a thiocompound which has long been used in the clinical setting, and has itself been clinically applied in cases of acute nickel-carbonyl poisoning (Sunderman, 1971) . According to previous studies (Brock & Pohl, 1983; Evans et al., 1984; Gale et al., 1982; Khanderkar, 1983) , DDTC protects against renal, gastrointestinal and bone marrow toxicity of cis-DDP and in appropriate treatment conditions it does not inhibit the antitumour effect of cis-DDP. The fact that uptake of 35S-labelled DDTC is greater in kidney, lung and bone marrow than in tumour tissue (Evans et al., 1983) (Evans et al., 1984) . I.p. injection was preferred to i.v. administration since the latter seems to favour delivery of DDTC to the kidney (Borch et al., 1980) . The other groups received a single i.v. injection of DX, CY or cis-DDP. Each anticancer drug was tested at three dose levels, whose range was selected on the basis of preliminary research on lethal effects of the drugs on the adopted strain of mice. LD50 at 21 days was 12, 200 and 15 mg kg-1 body weight respectively for DX, CY and cis-DDP. The doses adopted were as follows: DX 4.32, 7.20 and 12.00mgkg-1 body weight; CY 70, 120 and 200mgkg-1; cis-DDP 5.4, 9.0 and 15.0 mg kg-1. The remaining groups received a single i.v. dose of anticancer drug and 2 h later an i.p. administration of 1,000mg kg-1 of DDTC. Scheduling of DDTC at 2 h after the anticancer drug administration was based on results obtained by Bodenner et al. (1986a, b) on protection against cis-DDP toxicity by DDTC. Twenty-four hours after anticancer treatment (22 h after DDTC administration in the first group), under slight ether anaesthesia, mice were killed by cervical dislocation. Both femurs were removed and bone marrow suspensions were prepared. Bone marrow concentration of CFU-S and GM-CFC was determined (see below).
Methods
Bone marrow collection, preparation of bone marrow monodispersed cell suspensions and estimation of bone marrow cellularity were performed with the usual methods. A first aliquot of the bone marrow cell suspension was assayed for CFU-S content by the transplant method (Till & McCulloch, 1961 ). An aliquot of 0.5 ml of bone marrow cell suspension, diluted to contain 4 x 104 marrow cells, was injected into tail veins of nine recipient mice. Nine days after injection the host mice were killed under slight ether anaesthesia and their spleens were excised and fixed. The number of visible colonies was then counted, and the total number of CFU-S per femur (±standard error) was determined from the mean of the counts. To assay GM-CFC (Bradley & Metcalf, 1966 (Pannacciulli et al., 1982) . Normal values (±s.e.m.) in a group of untreated mice were bone marrow GM-CFC 11,375 + 1,187 per femur; bone marrow CFU-S 4,062 + 318 per femur. To prevent possible day-to-day variations in the assays, single data points obtained in treated mice and in controls were determined on the same day. The contents of CFU-S and GM-CFC per femur were normalised to those found in saline-treated controls. Student's t test was used for statistical comparison between the experimental groups.
Results
Effect of DDTC in a single 1,000mgkg-' injection on bone marrow CFU-S and GM-CFC The DDTC injection did not modify bone marrow or progenitor counts determined at 22 h after administration of the drug. At that time values in DDTC treated mice were bone marrow GM-CFC 11,190 + 1,451 colonies per femur; bone marrow CFU-S 3,974 + 366 colonies per femur. These values were not significantly different from those found in control mice (for each tested value P<0.01). DDTC 2 h after DX reduced the toxic effect of the latter on bone marrow CFU-S and CFC-C. Survival of CFU-S after the two lower doses of DX and that of GM-CFC following all doses of the anticancer drug were significantly higher than in controls. The protective effect of DDTC on GM-CFC was particularly striking.
Survival of bone marrow CFU-S and GM-CFC in mice 24h
Survival of bone marrow CFU-S and GM-CFC in mice 24h after CY or CY plus DDTC administration Following administration of increasing doses of CY survival of tested population resulted significantly decreased (P <0.01) (Figure 2 ). DDTC administered 2 h after CY increased survival of bone marrow GM-CFC at the lowest CY dose and that of bone marrow CFU-S following the two higher doses of the anticancer drug. Following the lowest CY dose CFU-S survival was higher in DDTC treated mice but the difference was not statistically significative.
Survival of bone marrow CFU-S and GM-CFC in mice 24h after cis-DDP or cis-DDP plus DDTC administration At every tested dose, cis-DDP caused a significant reduction in bone marrow CFU-S and GM-CFC (Figure 3 ). GM-CFC appeared to be more sensitive to cis-DDP than CFU-S. At cis-DDP doses of 5.4 and 9mgkg-1, survival of GM-CFC and of CFU-S was significantly (P<0.01) higher after cis-DDP plus DDTC than after cis-DDP alone. Following the 15mgkg-1 dose of cis-DDP, DDTC afforded no protection to these populations.
Discussion
Results here reported show that, on the whole, DDTC is able to reduce toxicity of cis-DDP, DX and CY on haemopoietic progenitors. Its effect is in general more evident following the lower dose of the drugs but, in the case of toxicity on bone marrow GM-CFC of DX and on bone marrow CFU-S of CY, the protective effect is extended to the higher doses of both drugs. This lack of correlation between CFU-S and GM-CFC response may be explained by the different kinetics of the tested population. In normal mice the former population has low proliferative activity while committed progenitors are actively proliferating.
Considering the interval (2 h) between anticancer drug administration and DDTC injection and plasma clearance half-times of DX (Formelli et al., 1985) , CY (Mellet, 1969) and cis-DDP (Brock & Pohl, 1983; Evans et al., 1984) in mice, the antitumour drugs probably reach target sites before DDTC administration. Thus the latter possibly operates interfering with the anticancer drug action at a cellular level.
The mechanism of the protective action of DDTC on haemopoietic progenitor toxicity of anticancer drug is not clear. DDTC may be able to delete cis-DDP bound to enzyme sulphydryl groups (Borch & Pleasants, 1979; DaleyYates & McBrien, 1982) or to reverse its inactivation of critical cellular proteins (Gonias et al., 1984) . The two hypotheses take into account the rather peculiar mechanism of action of cis-DDP, which contains a heavy metal. However, the protective action of DDTC seems to extend to a wider range of toxic mechanisms, since the compound can reduce the sensitivity of bone marrow stem cells to radiation (Evans et al., 1983) and to antineoplastic compounds other than cis-DDP, as shown by the results here reported.
DDTC, as other thiol donors, may protect tissues as a result of interference with free radical reactions (Harris & Philips, 1971; Yoda et al., 1986) . It has been proved that among anticancer drugs tested in this research, DX forms free radicals in various cell types and that they have a role in cardiac toxicity of the drug (Myers, 1982) . However, haemotoxicity of DX does not seem to be related to free radicals, and in our experience (Massa et al., 1985) , n-acetyl-cysteine did not appear to induce any consistent decrease in the toxicity of DX on haemopoietic progenitors. The results of the present work seem to show that DDTC does have this effect. The contrasting effects of the two thiol donors may be explained by the greater efficiency of DDTC as a thiol donor or by an inappropriate marrow penetration of n-acetyl-cysteine.
The intrinsic mechanism of the protective effect of DDTC on haemopoietic stem cells of CY-treated mice is still obscure as well. Thiol compounds, however, seem to be of great importance in modulating general cytotoxicity of alkylating agents (Ozols & Cowan, 1986; Tomashefsky et al., 1985) . For instance buthionine sulphoximine, an inhibitor of glutathione synthesis, may increase the toxicity of high doses of CY in tumour-bearing mice (Dorr et al., 1986) and in the present work DDTC seemed partially to protect haemopoietic progenitors from the toxic action of CY. In contrast mesna and n-acetyl-cysteine had no protective effect on haemopoietic stem cells of mice treated with CY (Millar et al., 1983; Massa et al., 1985) . As is the case with DX, the efficiency or the pharmacokinetics of DDTC may explain why it is more active than other thiol donors. The protective effect of DDTC on bone marrow CFU-S of mice treated with CY is intriguing considering that in vitro, probably as a result of the inhibition of aldehyde dehydrogenase activity, DDTC potentiates the cytotoxic action of 4-hydroperoxycyclophosphamide in the CFU-S assay (Khorn & Sladek, 1984) .
In conclusion, it emerges from the present work that DDTC reduces toxicity of anticancer drugs of different types on mice haemopoietic progenitors. Lack of parallel studies on tumour-bearing mice does not allow an assessment of the possible therapeutic advantages which could be had adding DDTC to tested cytotoxic drugs in cancer treatment. However, the results here reported on interaction between DDTC and DX, CY or cis-DDP at a haemopoietic level may be of significance. They suggest that this thiol donor merits further investigation in order to make a definite assessment of its selectivity and its possible future clinical exploitation.
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